U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H10N6O
Molecular Weight 182.1832
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DACARBAZINE

SMILES

CN(C)\N=N\C1=C(N=CN1)C(N)=O

InChI

InChIKey=FDKXTQMXEQVLRF-ZHACJKMWSA-N
InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+

HIDE SMILES / InChI

Molecular Formula C6H10N6O
Molecular Weight 182.1832
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DTIC-DOME

Approved Use

Dacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.

Launch Date

1.70380804E11
Primary
DTIC-DOME

Approved Use

Dacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.

Launch Date

1.70380804E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.2 μg/mL
750 mg/m² single, intravenous
dose: 750 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACARBAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14.8 μM × min
750 mg/m² single, intravenous
dose: 750 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACARBAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41.4 min
750 mg/m² single, intravenous
dose: 750 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACARBAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95%
DACARBAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503, 504
unhealthy, 34–79
n = 3
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 3
Sources: Page: p.503, 504
Disc. AE: Cerebral ischemia...
AEs leading to
discontinuation/dose reduction:
Cerebral ischemia (grade 4, 33%)
Sources: Page: p.503, 504
800 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 800 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503
unhealthy, 34–79
n = 16
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 16
Sources: Page: p.503
DLT: Thrombocytopenia...
Disc. AE: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 2, 6.25%)
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (grade 1, 6.25%)
Sources: Page: p.503
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Sources: Page: p.5
unhealthy, 40–65
n = 45
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 40–65
Sex: M+F
Population Size: 45
Sources: Page: p.5
Other AEs: Neutropenia, Fatigue...
Other AEs:
Neutropenia (grade 4, 2.2%)
Fatigue (grade 4, 2.2%)
Sources: Page: p.5
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Disc. AE: Leukopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Leukopenia (grade 3-5)
Thrombocytopenia (grade 3-5)
Anemia (sometimes)
Hematopoiesis impaired
Hepatotoxicity (grade 3-5, 0.01%)
Hepatic vein thrombosis (grade 3-5, 0.01%)
Necrosis hepatocellular (grade 3-5, 0.01%)
Anaphylaxis
Sources:
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Disc. AE: Anemia, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Anemia (mild)
Leukopenia (grade 3-5)
Thrombocytopenia (grade 3-5)
Hepatotoxicity (grade 3-5)
Hepatic vein thrombosis (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cerebral ischemia grade 4, 33%
Disc. AE
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503, 504
unhealthy, 34–79
n = 3
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 3
Sources: Page: p.503, 504
Thrombocytopenia grade 1, 6.25%
Disc. AE
800 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 800 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503
unhealthy, 34–79
n = 16
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 16
Sources: Page: p.503
Thrombocytopenia grade 2, 6.25%
DLT
800 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 800 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503
unhealthy, 34–79
n = 16
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 16
Sources: Page: p.503
Fatigue grade 4, 2.2%
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Sources: Page: p.5
unhealthy, 40–65
n = 45
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 40–65
Sex: M+F
Population Size: 45
Sources: Page: p.5
Neutropenia grade 4, 2.2%
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Sources: Page: p.5
unhealthy, 40–65
n = 45
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 40–65
Sex: M+F
Population Size: 45
Sources: Page: p.5
Anaphylaxis Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hematopoiesis impaired Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hepatic vein thrombosis grade 3-5, 0.01%
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hepatotoxicity grade 3-5, 0.01%
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Necrosis hepatocellular grade 3-5, 0.01%
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Leukopenia grade 3-5
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Thrombocytopenia grade 3-5
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Anemia sometimes
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hepatic vein thrombosis grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Hepatotoxicity grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Leukopenia grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Thrombocytopenia grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Anemia mild
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim
PubMed

PubMed

TitleDatePubMed
Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.
1975 Nov
[DTIC: effect on fibrinolysis and thrombocyte function].
1986 Oct
Peripheral DTIC neurotoxicity: a case report.
1987
[Hepatic veno-occlusive disease caused by Deticene: a cause of acute hypovolemic shock].
1990
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
2000 Jan
Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase.
2000 Oct
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
2001 Feb
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
2002
Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
2002 Aug
Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
2002 Jan 1
Metastatic melanoma presenting as cardiac mass and hemobilia.
2003 Mar
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
2004 Dec
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
2004 Jun 1
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
2005 Dec
Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
2005 Jun
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.
2005 Jun
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
2005 Oct
Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
2006 Aug-Sep
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
2007
Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature.
2007 Jun
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
2007 Jun
Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
2007 Nov-Dec
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas.
2008 Apr
Cerebellar dysfunction caused by procarbazine and consumption of excessive amount of bananas.
2008 Jun
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
2009 Jun
Patents

Sample Use Guides

Malignant Melanoma: the recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals Hodgkin's Disease: The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks.5 An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days
Route of Administration: Intravenous
The effect of alkyating agent dacarbazine (DTIC) and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). Growth inhibition in vitro was additive with the two drugs. There was no effect on drug uptake or on the number of DNA strand breaks. There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. Co-administration of the two drugs in mice caused an increase in the area under the curve of both drugs, but the combination was not effective in reducing human A375 melanoma tumors in vivo.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:37:07 UTC 2023
Edited
by admin
on Wed Jul 05 23:37:07 UTC 2023
Record UNII
7GR28W0FJI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DACARBAZINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
DACARBAZINE [WHO-IP]
Common Name English
DIC
Common Name English
DTIC
Common Name English
DACARBASINE
Common Name English
dacarbazine [INN]
Common Name English
1H-IMIDAZOLE-4-CARBOXAMIDE, 5-(3,3-DIMETHYL-1-TRIAZENYL)-
Systematic Name English
DACARBAZINE [ORANGE BOOK]
Common Name English
Dacarbazine [WHO-DD]
Common Name English
DACARBAZINE [USP MONOGRAPH]
Common Name English
DACARBAZINE [HSDB]
Common Name English
DTIC-DOME
Brand Name English
DACARBAZINE [USP-RS]
Common Name English
DACARBAZINE [MI]
Common Name English
DACARBAZINE [VANDF]
Common Name English
DECARBAZINE
Common Name English
NSC-45388
Code English
NCI C04717
Code English
DACARBAZINE [IARC]
Common Name English
DACARBAZINE [EP MONOGRAPH]
Common Name English
IMIDAZOLE CARBOXAMIDE
Systematic Name English
DACARBAZINE [USAN]
Common Name English
DACARBAZINE [MART.]
Common Name English
DACARBAZINUM [WHO-IP LATIN]
Common Name English
DACARBAZINE [JAN]
Common Name English
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
Systematic Name English
BIOCARBAZINE R
Common Name English
DICARBAZINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C902
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
LIVERTOX NBK548913
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
WHO-ATC L01AX04
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
NDF-RT N0000175558
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
WHO-VATC QL01AX04
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
Code System Code Type Description
RS_ITEM_NUM
1162308
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
DAILYMED
7GR28W0FJI
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
SMS_ID
100000088395
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
INN
3232
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
FDA UNII
7GR28W0FJI
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
DRUG BANK
DB00851
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
NSC
45388
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
LACTMED
Dacarbazine
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
WIKIPEDIA
DACARBAZINE
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
HSDB
3219
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
CAS
4342-03-4
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
NCI_THESAURUS
C411
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID0020369
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
PUBCHEM
135398738
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
ECHA (EC/EINECS)
224-396-1
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL476
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DACARBAZINE
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY Description: A colourless or pale yellow, crystalline powder.Solubility: Slightly soluble in water and ethanol (~750 g/l) TS.Category: Cytotoxic drug.Storage: Dacarbazine should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 8 ?C.Additional information: CAUTION: Dacarbazine must be handled with care, avoiding contact with the skin and inhalation ofairborne particles.
MERCK INDEX
M4065
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY Merck Index
CHEBI
4305
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
EVMPD
SUB06882MIG
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
MESH
D003606
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
DRUG CENTRAL
773
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY
RXCUI
3098
Created by admin on Wed Jul 05 23:37:08 UTC 2023 , Edited by admin on Wed Jul 05 23:37:08 UTC 2023
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
Km
METABOLIC ENZYME -> SUBSTRATE
Vmax
METABOLIC ENZYME -> SUBSTRATE
Vmax
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Km
METABOLIC ENZYME -> SUBSTRATE
Km
Related Record Type Details
METABOLITE INACTIVE -> PARENT
Plasma exposure to AIC was equivalent to that of DTIC, whereas urinary recovery of DTIC and AIC was low and highly variable.
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
PLASMA
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC